Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Ocular drugs and drug delivery systems - Current trends and future perspectives.

Rupenthal ID, Daugherty AL.

Drug Discov Today. 2019 Aug;24(8):1425-1426. doi: 10.1016/j.drudis.2019.07.005. Epub 2019 Jul 19. No abstract available.

PMID:
31330186
2.

Topical semifluorinated alkane-based azithromycin suspension for the management of ocular infections.

Agarwal P, Craig JP, Krösser S, Eickhoff K, Swift S, Rupenthal ID.

Eur J Pharm Biopharm. 2019 Sep;142:83-91. doi: 10.1016/j.ejpb.2019.06.008. Epub 2019 Jun 11.

PMID:
31195132
3.

Corrigendum to "Overcoming ocular drug delivery barriers through the use of physical forces" [Advanced Drug Delivery Reviews 126 (2018) 96-112].

Huang D, Chen YS, Rupenthal ID.

Adv Drug Deliv Rev. 2019 Jan 15;139:157. doi: 10.1016/j.addr.2019.05.006. Epub 2019 May 24. No abstract available.

PMID:
31133328
4.

Connexin43 hemichannel block protects against retinal pigment epithelial cell barrier breakdown.

Kuo C, Green CR, Rupenthal ID, Mugisho OO.

Acta Diabetol. 2019 Apr 27. doi: 10.1007/s00592-019-01352-3. [Epub ahead of print]

PMID:
31030263
5.

Depot formulations to sustain periocular drug delivery to the posterior eye segment.

Agban Y, Thakur SS, Mugisho OO, Rupenthal ID.

Drug Discov Today. 2019 Aug;24(8):1458-1469. doi: 10.1016/j.drudis.2019.03.023. Epub 2019 Mar 28. Review.

PMID:
30930148
6.

Ex vivo evaluation of the stability, safety and antibacterial efficacy of an extemporaneous povidone-iodine preparation for ophthalmic applications.

Lee S, Khun D, Kumarasinghe GL, De Zoysa GH, Sarojini V, Vellara HR, Rupenthal ID, Thakur SS.

Clin Exp Optom. 2019 Mar 28. doi: 10.1111/cxo.12899. [Epub ahead of print]

PMID:
30924199
7.

Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics.

Agarwal P, Khun D, Krösser S, Eickhoff K, Wells FS, Willmott GR, Craig JP, Rupenthal ID.

Ocul Surf. 2019 Apr;17(2):241-249. doi: 10.1016/j.jtos.2019.02.010. Epub 2019 Mar 2.

PMID:
30831252
8.

Connexin43 hemichannels: A potential drug target for the treatment of diabetic retinopathy.

Mugisho OO, Green CR, Zhang J, Acosta ML, Rupenthal ID.

Drug Discov Today. 2019 Aug;24(8):1627-1636. doi: 10.1016/j.drudis.2019.01.011. Epub 2019 Jan 25. Review.

PMID:
30690195
9.

Ultrasound-responsive nanobubbles for enhanced intravitreal drug migration: An ex vivo evaluation.

Thakur SS, Chen YS, Houston ZH, Fletcher N, Barnett NL, Thurecht KJ, Rupenthal ID, Parekh HS.

Eur J Pharm Biopharm. 2019 Mar;136:102-107. doi: 10.1016/j.ejpb.2019.01.014. Epub 2019 Jan 17.

PMID:
30660691
10.

Connexin43 hemichannel block protects against the development of diabetic retinopathy signs in a mouse model of the disease.

Mugisho OO, Green CR, Squirrell DM, Bould S, Danesh-Meyer HV, Zhang J, Acosta ML, Rupenthal ID.

J Mol Med (Berl). 2019 Feb;97(2):215-229. doi: 10.1007/s00109-018-1727-5. Epub 2018 Dec 8.

PMID:
30535867
11.

Evaluation of 2 ex vivo Bovine Cornea Storage Protocols for Drug Delivery Applications.

Thakur SS, Shrestha D, Rupenthal ID.

Ophthalmic Res. 2019;61(4):204-209. doi: 10.1159/000493488. Epub 2018 Nov 22.

PMID:
30466090
12.

Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: Modelling signs of diabetic retinopathy.

Mugisho OO, Rupenthal ID, Squirrell DM, Bould SJ, Danesh-Meyer HV, Zhang J, Green CR, Acosta ML.

PLoS One. 2018 Aug 22;13(8):e0202156. doi: 10.1371/journal.pone.0202156. eCollection 2018.

13.

Intracellular oligonucleotide delivery using the cell penetrating peptide Xentry.

Coutinho FP, Green CR, Rupenthal ID.

Sci Rep. 2018 Jul 26;8(1):11256. doi: 10.1038/s41598-018-29556-7.

14.

Sustained Connexin43 Mimetic Peptide Release From Loaded Nanoparticles Reduces Retinal and Choroidal Photodamage.

Mat Nor N, Guo CX, Rupenthal ID, Chen YS, Green CR, Acosta ML.

Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3682-3693. doi: 10.1167/iovs.17-22829.

PMID:
30029255
15.

Drug delivery to the lens for the management of cataracts.

Thrimawithana TR, Rupenthal ID, Räsch SS, Lim JC, Morton JD, Bunt CR.

Adv Drug Deliv Rev. 2018 Feb 15;126:185-194. doi: 10.1016/j.addr.2018.03.009. Epub 2018 Mar 28. Review.

PMID:
29604375
16.

Hyaluronic acid coated albumin nanoparticles for targeted peptide delivery in the treatment of retinal ischaemia.

Huang D, Chen YS, Green CR, Rupenthal ID.

Biomaterials. 2018 Jun;168:10-23. doi: 10.1016/j.biomaterials.2018.03.034. Epub 2018 Mar 20.

PMID:
29597134
17.

Micelle directed chemical polymerization of polypyrrole particles for the electrically triggered release of dexamethasone base and dexamethasone phosphate.

Uppalapati D, Sharma M, Aqrawe Z, Coutinho F, Rupenthal ID, Boyd BJ, Travas-Sejdic J, Svirskis D.

Int J Pharm. 2018 May 30;543(1-2):38-45. doi: 10.1016/j.ijpharm.2018.03.039. Epub 2018 Mar 23.

PMID:
29581065
18.

Effects of enzymatic degradation on dynamic mechanical properties of the vitreous and intravitreal nanoparticle mobility.

Huang D, Chen YS, Xu Q, Hanes J, Rupenthal ID.

Eur J Pharm Sci. 2018 Jun 15;118:124-133. doi: 10.1016/j.ejps.2018.03.023. Epub 2018 Mar 21.

PMID:
29574081
19.

Development of a novel stability indicating RP-HPLC method for quantification of Connexin43 mimetic peptide and determination of its degradation kinetics in biological fluids.

Bisht R, Rupenthal ID, Sreebhavan S, Jaiswal JK.

J Pharm Anal. 2017 Dec;7(6):365-373. doi: 10.1016/j.jpha.2017.06.008. Epub 2017 Jun 23.

20.

Randomised masked trial of the clinical safety and tolerability of MGO Manuka Honey eye cream for the management of blepharitis.

Craig JP, Wang MTM, Ganesalingam K, Rupenthal ID, Swift S, Loh CS, Te Weehi L, Cheung IMY, Watters GA.

BMJ Open Ophthalmol. 2017 Aug 4;1(1):e000066. doi: 10.1136/bmjophth-2016-000066. eCollection 2017.

Supplemental Content

Loading ...
Support Center